Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSD-101 in EBV-associated Nasopharyngeal Carcinoma
NCT06097793Phase 1Recruiting
- Sponsor
- Kousai Bio
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous monocyte-derived DCs pulsed with EBV antigen in nasopharyngeal carcinoma (NPC), sponsored by Kousai Bio. Primary endpoint: Safety endpoint at 1 year. Started Dec 2023; status: recruiting.
02
Drugs
autologous monocyte-derived DCs pulsed with EBV antigen
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06097793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06097793.